Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Merck KGaA buys Amptec for mRNA tech and Chimerix acquires Oncoceutics for cancer pipeline.
Cullinan Management Inc. and Gracell Biotechnologies, two biotech IPOs that focus on cancer research and developing new oncology treatments, set their terms and are set to start trading on Friday January, 8.
Although they don’t necessarily agree on numbers, most reports indicate that 2020 was not a particularly good year for mergers and acquisitions in the biopharma industry.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
BioSpace highlights a number of the key M&A deals struck over the past 12 months.
Shares of NantKwest were up more than 27% in premarket trading after the company announced a stock-for-stock reverse merger with privately-held ImmunityBio.
The company bolstered its presence in oncology with the acquisition of the clinical and research-stage oncology business of Agios in a deal worth up to $2 billion.
Novartis is acquiring Cambridge, Massachusetts-based Cadent Therapeutics for $210 million up front and a possible $560 million in milestone payments.
Shares of Prevail Therapeutics have skyrocketed more than 84% in premarket trading after Eli Lilly announced it was acquiring the gene therapy company in a deal valued at approximately $1.04 billion.
The deal has been approved by both companies’ boards and is expected to close in the third quarter of 2021.